Medifast (MED) Cash & Equivalents (2010 - 2026)

Medifast has reported Cash & Equivalents for 17 years, with the latest figure at $71.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 22.01% year-over-year to $71.5 million; the trailing twelve-month figure through Mar 2026 stood at $71.5 million (down 22.01% YoY), and the FY2025 full-year result was $89.3 million, down 1.79% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $71.5 million, down from $89.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $147.4 million in Q2 2023, with the low at $61.1 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $98.8 million across 5 years, with a median of $97.5 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 68.19% — and 2023, when it surged 141.37%.
• Medifast's Cash & Equivalents stood at $87.7 million in 2022, then gained by 7.7% to $94.4 million in 2023, then dropped by 3.72% to $90.9 million in 2024, then retreated by 1.79% to $89.3 million in 2025, then dropped by 19.9% to $71.5 million in 2026.
• The last three Cash & Equivalents figures came in at $71.5 million (Q1 2026), $89.3 million (Q4 2025), and $99.5 million (Q3 2025), per Business Quant data.